At a glance
- Originator Pfizer
- Class Antidepressants; Anxiolytics; Obesity therapies
- Mechanism of Action Serotonin 1B receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 15 Mar 2000 No-Development-Reported for Obesity (Unknown route)
- 10 Sep 1998 Preclinical development for Obesity (Unknown route)